Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background: Immune checkpoint blockade (ICB) has transformed cancer therapy, with long-term responses and a favorable safety profile; however, only a minority of patients respond. Response to ICB is influenced by immune-related genetic factors such as HLA haplotype, potentially including patient blood type and associated differences in diversity of the T-cell repertoire. A minority of patients experience immune-related adverse events (irAEs), with unclear relation to response or resistance. Materials and Methods: In this single institution study, we aimed to investigate the relationship of time to treatment failure (TTF) with patient blood type and with occurrence of irAEs, among patients with metastatic cancer receiving ICB. Results: We found a strong association of improved TTF with presence of irAEs, and also among patients with type O blood, compared with type A/B/AB blood. Among patients with type O blood, TTF was substantially longer among those experiencing an irAE (n = 44; adjusted HR 0.41, 95% CI 0.18,0.96). For patients with type A/B/AB blood, no significant association was present (n = 63; adjusted HR 0.69, 95% CI 0.39,1.21). For type O patients, median TTF of ICB was 13.4 months (95% CI: 3.79 months, NA) vs 2.55 months (95% CI: 1.95 months, 4.95 months) for other patients. Conclusion: This retrospective study of a cohort of patients receiving ICB suggests a preferential benefit among patients with type O blood and, in particular, among patients with type O blood who developed irAEs. Validation in future independent cohorts and investigation of a potential biologic basis for this finding is warranted.

References Powered by Scopus

Roles of the immune system in cancer: From tumor initiation to metastatic progression

1512Citations
N/AReaders
Get full text

Positive and negative selection of the T cell repertoire: What thymocytes see (and don't see)

1011Citations
N/AReaders
Get full text

Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma

971Citations
N/AReaders
Get full text

Cited by Powered by Scopus

ABO-Blood Group Associates With Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

0Citations
N/AReaders
Get full text

Predictors of the immunochemotherapy effectiveness of atezolizumab in combination with etoposide and carboplatin in patients with advanced small cell lung cancer

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chen, R., Hakimi, K., Zhang, X., Messer, K., & Patel, S. P. (2022). Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer. Oncologist, 27(9), e739–e745. https://doi.org/10.1093/oncolo/oyac128

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

50%

Business, Management and Accounting 1

50%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free